A Novel Circular Delta‐XBB.1.5 RBD Dimeric Protein Subunit Vaccine Mediated by Split Intein Elicits an Immune Response and Protection Against Multiple SARS‐CoV‐2 Variants in Mice
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.70134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Kangyin Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Antibodies, Neutralizing, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB0490000), the National Key R&D Program of C….
Abstract (Originalsprache)
SARS‐CoV‐2 continues to mutate, leading to breakthrough infections. The development of new vaccine strategies to combat various strains is crucial. Protein cyclization can enhance thermal stability and may improve immunogenicity. Here, we designed a cyclic tandem dimeric receptor‐binding domain protein (cirRBD2) via the split intein Cth‐Ter. Cyclization does not affect the antigen epitopes of RBD but results in better thermal stability than that of its linear counterpart (linRBD2). Compared with the mice immunized with linRBD2, those immunized with two doses of 5 μg of cirRBD2 produced significantly greater levels of broad‐spectrum neutralizing antibodies, and generated a considerable cellular immune response. In the VEEV‐VRP‐hACE2‐transduced mouse model, two doses of 5 μg of cirRBD2 provided protection against infection with BA.5, XBB.1.9, and partial protection against EG.5 which has more mutations. This study developed a novel circular RBD dimer subunit vaccine for SARS‐CoV‐2 that exhibits broad‐spectrum neutralizing activity against various variants. A similar strategy can be applied to develop vaccines for other pathogens, especially for thermally stable vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
- University of the Chinese Academy of Sciences, Beijing, China.
- Department of Immunology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
- Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, China.
ORCID-Profile: Bo Zhang, Huajun Zhang
Förderung
- This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB0490000), the National Key R&D Program of C…
Zitieren
APA
Li, K., Wu, Y., Zhang, H., Chen, S., Wu, B., Li, T., Li, E., Luo, F., Jin, A., Zhang, B., Zhang, Y., Gong, R., Zhang, H., & Chiu, S. (2024). A Novel Circular Delta‐XBB.1.5 RBD Dimeric Protein Subunit Vaccine Mediated by Split Intein Elicits an Immune Response and Protection Against Multiple SARS‐CoV‐2 Variants in Mice. Journal of Medical Virology. https://doi.org/10.1002/jmv.70134
Vancouver
Li K, Wu Y, Zhang H, Chen S, Wu B, Li T, et al. A Novel Circular Delta‐XBB.1.5 RBD Dimeric Protein Subunit Vaccine Mediated by Split Intein Elicits an Immune Response and Protection Against Multiple SARS‐CoV‐2 Variants in Mice. Journal of Medical Virology. 2024. doi:10.1002/jmv.70134
BibTeX
@article{Li2024,
author = {Li, Kangyin and Wu, Yan and Zhang, Hongqing and Chen, Shaohong and Wu, Bihao and Li, Tingting and Li, Entao and Luo, Feiyang and Jin, Aishun and Zhang, Bo and Zhang, Yanan and Gong, Rui and Zhang, Huajun and Chiu, Sandra},
title = {A Novel Circular Delta‐XBB.1.5 RBD Dimeric Protein Subunit Vaccine Mediated by Split Intein Elicits an Immune Response and Protection Against Multiple SARS‐CoV‐2 Variants in Mice},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.70134}
}
EUVIMED